Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 739-746

  Kondo, S ^a   Ueno, H ^a   Hosoi, H ^a   Hashimoto, J ^a   Morizane, C ^a   Koizumi, F ^a   Tamura, K ^a   Okusaka, T ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GEMCITABINE; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; PENTRAXIN 3;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL MIGRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; C-REACTIVE PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; DEOXYCYTIDINE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SERUM AMYLOID P-COMPONENT; TRANSFECTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84883159888     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.348     Document Type: Article

References (34)

1. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A (1994) Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 84(10): 3483-3493.
2. Basile A, Moschetta M, Ditonno P, Ria R, Marech I, De Luisi A, Berardi S, Frassanito MA, Angelucci E, Derudas D, Specchia G, Curci P, Pavone V, Rossini B, Ribatti D, Bottazzi B, Mantovani A, Presta M, Dammacco F, Vacca A (2013) Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. J Pathol 229(1): 87-98.
3. Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG (2008) Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26(36): 5918-5922.
4. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20(15): 3270-3275.
5. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6): 2403-2413.
6. Camozzi M, Rusnati M, Bugatti A, Bottazzi B, Mantovani A, Bastone A, Inforzato A, Vincenti S, Bracci L, Mastroianni D, Presta M (2006) Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 281(32): 22605-22613.
7. DeNardo DG, Johansson M, Coussens LM (2008) Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 27(1): 11-18.
8. Dessein AF, Stechly L, Jonckheere N, Dumont P, Monté D, Leteurtre E, Truant S, Pruvot FR, Figeac M, Hebbar M, Lecellier CH, Lesuffleur T, Dessein R, Grard G, Dejonghe MJ, de Launoit Y, Furuichi Y, Prévost G, Porchet N, Gespach C, Huet G (2010) Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res 70(11): 4644-4654.
9. Diamandis EP, Goodglick L, Planque C, Thornquist MD (2011) Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 17(8): 2395-2399.
10. Doni A, Mantovani G, Porta C, Tuckermann J, Reichardt HM, Kleiman A, Sironi M, Rubino L, Pasqualini F, Nebuloni M, Signorini S, Peri G, Sica A, Beck-Peccoz P, Bottazzi B, Mantovani A (2008) Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells. J Biol Chem 283(44): 29983-29992.
11. Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L, Romani L, Garlanda C, Mantovani A (2003) Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 33(10): 2886-2893.
12. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R (2004) Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101(12): 2727-2736.
13. Garlanda C, Bottazzi B, Bastone A, Mantovani A (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337-366.
14. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P (2010) Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 70(6): 2235-2244.
15. Han B, Mura M, Andrade CF, Okutani D, Lodyga M, dos Santos CC, Keshavjee S, Matthay M, Liu M (2005) TNFalpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J Immunol 175(12): 8303-8311.
16. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25(16): 2212-2217.
17. Jaillon S, Peri G, Delneste Y, Frémaux I, Doni A, Moalli F, Garlanda C, Romani L, Gascan H, Bellocchio S, Bozza S, Cassatella MA, Jeannin P, Mantovani A (2007) The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 204(4): 793-804.
18. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
19. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, Mantovani A (2004) Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175(2): 221-228.
20. Kondo S, Iwata S, Yamada T, Inoue Y, Ichihara H, Kichikawa Y, Katayose T, Souta-Kuribara A, Yamazaki H, Hosono O, Kawasaki H, Tanaka H, Hayashi Y, Sakamoto M, Kamiya K, Dang NH, Morimoto C (2012a) Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer. Clin Cancer Res 18(22): 6326-6338.
21. Kondo S, Ueno H, Hashimoto J,Morizane C, Koizumi F, Okusaka T, Tamura K (2012b) Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy. BMC Cancer 12(1): 268.
22. Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, Indraccolo S, Presta M (2011) Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumours. Mol Cancer Ther 10(9): 1600-1610.
23. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203): 436-444.
24. Morizane C, Okusaka T, Morita S, Tanaka K, Ueno H, Kondo S, Ikeda M, Nakachi K, Mitsunaga S (2011) Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas 40(3): 415-421.
25. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL (2008) Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 28(5): 925-931.
26. Polentarutti N, Picardi G, Basile A, Cenzuales S, Rivolta A, Matteucci C, Peri G, Mantovani A, Introna M (1998) Interferon-gamma inhibits expression of the long pentraxin PTX3 in human monocytes. Eur J Immunol 28(2): 496-501.
27. Ravenna L, Sale P, Di Vito M, Russo A, Salvatori L, Tafani M, Mari E, Sentinelli S, Petrangeli E, Gallucci M, Di Silverio F, Russo MA (2009) Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate 69(11): 1245-1255.
28. Sardana G, Jung K, Stephan C, Diamandis EP (2008) Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 7(8): 3329-3338.
29. Tafani M, Russo A, Di Vito M, Sale P, Pellegrini L, Schito L, Gentileschi S, Bracaglia R, Marandino F, Garaci E, Russo MA (2010) Up-regulation of pro-inflammatory genes as adaptation to hypoxia in MCF-7 cells and in human mammary invasive carcinoma microenvironment. Cancer Sci 101(4): 1014-1023.
30. Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Hagihara A, Iwasa S, Kojima Y (2008) Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 38(11): 755-761.
31. Ueno H, Okada S, Okusaka T, Ikeda M (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59(4): 296-301.
32. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378(9791): 607-620.
33. Willeke F, Assad A, Findeisen P, Schromm E, Grobholz R, von Gerstenbergk B, Mantovani A, Peri S, Friess HH, Post S, von Knebel Doeberitz M, Schwarzbach MH (2006) Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer 42(15): 2639-2646.
34. Winner M, Koong AC, Rendon BE, Zundel W, Mitchell RA (2007) Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res 67(1): 186-193.